Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Open-Label, Randomized, Multicenter Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease

Next Previous
Trial Profile

A Phase 2, Open-Label, Randomized, Multicenter Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 07 Dec 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Axatilimab (Primary) ; Corticosteroids (Primary) ; Methylprednisolone (Primary) ; Prednisone (Primary) ; Ruxolitinib (Primary)
  • Indications Graft-versus-host disease
  • Focus Therapeutic Use
  • Sponsors Incyte Corporation

Most Recent Events

  • 03 Nov 2025 According to a Syndax Pharmaceuticals media release, data form the trial will be presented at the 67th American Society of Hematology (ASH) Annual Meeting being held in Orlando, Florida, December 6-9, 2025.
  • 03 Nov 2025 According to a Syndax Pharmaceuticals media release, data form the trial were accepted for presentation at the 67th American Society of Hematology (ASH) Annual Meeting being held in Orlando, Florida, December 6-9, 2025.
  • 14 Oct 2024 Planned initiation date changed from 29 Sep 2024 to 17 Oct 2024.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top